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Abstract
Hepatocellular carcinoma (HCC) is a major public health problem due to increased incidence, late diagnosis and
limited treatment options. TGF-β is known to provide cytostatic signals during early stages of liver damage and
regeneration, but exerts tumor promoting effects in onset and progression of liver cancer. To understand the
mechanistic background of such a switch, we systematically correlated loss of cytostatic TGF-β effects with strength
and dynamics of its downstream signaling in 10 HCC cell lines. We demonstrate that TGF-β inhibits proliferation and
induces apoptosis in cell lines with low endogenous levels of TGF-β and Smad7 and strong transcriptional Smad3
activity (PLC/PRF/5, HepG2, Hep3B, HuH7), previously characterized to express early TGF-β signatures correlated
with better outcome in HCC patients. TGF-β dependent cytostasis is blunted in another group of cell lines (HLE, HLF,
FLC-4) expressing high amounts of TGF-β and Smad7 and showing significantly reduced Smad3 signaling. Of those,
HLE and HLF exhibit late TGF-β signatures, which is associated with bad prognosis in HCC patients. RNAi with
Smad3 blunted cytostatic effects in PLC/PRF/5, Hep3B and HuH7. HCC-M and HCC-T represent a third group of cell
lines lacking cytostatic TGF-β signaling despite strong and prolonged Smad3 phosphorylation and low Smad7 and
TGF-β expression. Inhibitory linker phosphorylation, as in HCC-T, may disrupt C-terminally phosphorylated Smad3
function. In summary, we assort 10 HCC cell lines in at least two clusters with respect to TGF-β sensitivity. Cell lines
responsive to the TGF-β cytostatic program, which recapitulate early stage of liver carcinogenesis exhibit
transcriptional Smad3 activity. Those with disturbed TGF-β/Smad3 signaling are insensitive to TGF-β dependent
cytostasis and might represent late stage of the disease. Regulation of this switch remains complex and cell line
specific. These features may be relevant to discriminate stage dependent TGF-β functions for the design of efficient
TGF-β directed therapy in liver cancer.
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Introduction
HCC is the third most lethal cancer in the world with
dramatically rising incidence [1,2]. Limited treatment options
and delayed diagnosis caused by late occurring symptoms [3]
highlight the urgent need to characterize the heterogeneity of
oncogenic mechanisms in HCC and to identify early disease
biomarkers and new drugable targets.
TGF-β, a multifunctional cytokine, signals via canonical
Smad dependent and non-canonical Smad independent
pathways regulating the expression of more than 500 genes.
Canonically, TGF-β binds to TGF-β receptors type II (TβRII)
which subsequently recruit and activate the type I receptors
TβRI/ALK-5 by phosphorylation, leading to downstream C-
terminal phosphorylation of receptor (R)-Smad proteins.
Phospho-activated R-Smads then complex common mediator
(Co)-Smad4, translocate into the nucleus and act as
transcription factors in concert with co-activators and co-
repressors [4].
TGF-β is prominent in damaged liver and represents a key
regulator of hepatic stellate cell activation and liver fibrogenesis
upon most types of liver damage. It displays cytostatic effects
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inducing apoptosis in distinct hepatocytes and interfering with
hepatocyte proliferation during liver regeneration. Chronic liver
damage frequently progresses towards cirrhosis and HCC.
During this process, TGF-β is assumed to switch from
cytostatic to oncogenic action on hepatocytes becoming a
plasticity factor that induces epithelial mesenchymal transition
(EMT), cytokine and receptor production, migration and
invasion.
Malignant cells can circumvent the cytostatic effects of TGF-
β either by mutational inactivation of core pathway
components, as TGF-β receptors or Smad proteins, or by
interfering with cytostatic branches of TGF-β signaling (for
review, 5). Such mutations were described in colorectal,
pancreatic, ovarian, gastric, and head and neck carcinomas [5],
whereas they are rare in HCC [6]. This indicates that
transformed hepatocytes principally retain an intact TGF-β
signaling machinery with alterations of the tumor-suppressive
arm only. Although missing a general mechanism of this
process in HCC, several studies have provided hypotheses.
Thus, a link between deletion of the adaptor protein ELF,
expression of its inhibitor PRAJA and defective Smad3
signaling leading to significant liver disease was reported [7,8].
Further, constitutively activated Ras was shown to act as
initiating step switching TGF-β effects from cytostatic to
tumorigenic [9]. TGF-β inhibitory Smad7 was found
upregulated in a limited number of investigated patients
[10,11]. Then JNK mediated linker phosphorylation of Smad3
inactivated cytostatic Smad3 signaling and facilitated
hepatocarciongenesis [12]. Although such dual role of TGF-β
has long been noted and potential routes for a tumorigenic
switch were described, robust mechanistic markers to sub
classify patient cohorts are still not available. This is, however,
of utmost relevance since TGF-β directed therapy is currently
envisaged and clinical trials are underway for late stage HCC
patients.
In order to expand the knowledge, we thoroughly
investigated TGF-β signaling and cytostatic effects in 10 HCC
cell lines, for the first time under strictly comparable conditions.
Our results highlight the heterogeneity of HCC cell lines in
response to TGF-β, but allowed identification and
characterization of two general groups - one being responsive
the other being insensitive to TGF-β-induced cytostatic
program (i.e. inhibition of proliferation and/or induction of cell
death). While the former expressed low endogenous TGF-β
and Smad7 levels and showed significant Smad3
transcriptional activity, the latter exhibited the opposite
features. We concluded that although HCC cell lines are
generally thought to represent late stages of liver cancer, they
display a diverse picture regarding TGF-β signaling. In line with
heterogeneity of HCC tumors in patients, the heterogeneity of
HCC cell lines obviously reflects different stages and
mechanisms of the disease. Thus, our results provide a unique
opportunity to select relevant HCC cell lines to investigate
specific (especially TGF-β related mechanisms) driving HCC
onset and progression.
Materials and Methods
LDH Assay
After starvation for 8h, cells were treated with TGF-β for 72h.
For HCC-M and HuH7, starvation medium was supplemented
with 1% heat inactivated FCS. LDH content in supernatant and
adherent cells (disrupted with 1% Triton X-100 in HBSS) was
detected using Cytotoxicity Detection Kit (Roche Diagnostics
GmbH, Mannheim, Germany). Cell death was calculated as
percentage of LDH in the medium as compared to total LDH
levels.
MTT Assay
Cells were cultured in medium containing 0.25% heat
inactivated FCS with 5ng/ml TGF-β for 2 or 6 days (addition of
new FCS and TGF-β after 3 days). 4h after adding MTT
reagent (final concentration 500µg/ml), reduced dye in viable
cells was resolved in acidified DMSO solution (10% SDS, 0.6%
glacial acid in DMSO). Absorbance was measured at 570nm
(reference 630nm). Values of treated samples were normalized
to untreated controls.
RNA Extraction, Reverse Transcription, Real Time PCR
Analysis
HCC cell lines were treated with TGF-β for 2 or 24h. RNA
was isolated using RNeasy Mini Kit, integrity ensured by
agarose gel electrophoreses and reverse transcribed using
QuantiTect Reverse Transcription Kit (QIAGEN, Hilden,
Germany). mRNA levels of Smad7, TGF-β1, TβRI, TβRII and
18S-rRNA were detected using TaqMan® probes and
TaqMan® Universal PCR Master Mix, No AmpErase® UNG;
PRAJA, ELF, Bim, PAI-1 and 18S-RNA using Power SYBR®
Green PCR Master Mix (Applied Biosystems, Foster City, CA,
USA). Primer pairs used for SYBR green Real time PCR were
as followed: PRAJA (For: 5’-
TCGCCATTTTCCACTACTCGT-3’; Rev: 5’-
GTTCCCGAACTCTCGCTGT-3’), ELF (For: 5’-
AGCTGGAAGGCAGATTCAAG-3’; Rev 5’-
CGTCCATCTCGAAGGTCAGT-3’), Bim (For: 5’-
TAAGTTCTGAGTGTGACCGAGA-3’; Rev 5’-
GCTCTGTCTGTAGGGAGGTAGG-3’), PAI-1 (For: 5’-
CACAAATCAGACGGCAGCACT-3’; Rev 5’-
CATCGGGCGTGGTGAACTC-3’), Smad4 (For: 5’-
GCTGCTGGAATTGGTGTTGATG-3’; Rev 5’-
AGGTGTTTCTTTGATGCTCTGTCT-3’) and 18S rRNA (For:
5’- AAACGGCTACCACATCCAAG-3’; Rev 5’-
CCTCCAATGGATCCTCGTTA-3’). Following assays were
obtained from Applied Biosystems and used for TaqMan, Real
time PCR: Smad (Hs00178696_m1), TGF-β1
(Hs00171257_m1), TGFBR1 (TβRI, Hs00610318_m1),
TGFBR2 (TβRII, Hs00559661_m1), Smad2 (Hs00998181_gH),
Smad3 (Hs00969205_g1) and 18S rRNA (Hs03003631_g1).
Relative expression levels were determined using the ΔΔCt
method (reference 18S-rRNA level). As 18S-rRNA expression
values are very stable (see Figure S1) only one reference gene
was used according to literature [13].
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Immunoblot Analysis
Blotted proteins were detected using antibodies against
pSmad2C (Ser465/467), Smad2 (D43B4), Smad3, Akt, pAKT
(Ser473) (587F11), pc-JUN (Ser63), pP38 MAPK (Thr180/
Tyr182) (12F8), cleaved Caspase-3 (Asp175) (5A1E), PARP,
BCL-2 (50E3) and BCL-XL (54H6) (Cell Signaling Technology,
Danvers, MA, USA), Smad4 (B-8), PCNA (F-2), c-MYC
(2Q329), ERK1/2 (MK1) and pERK (E-4) (Santa Cruz
Biotechology, Santa Cruz, California, USA.), P21WAF1/Cip1
(CP74) (Sigma Aldrich, St. Louis, Missouri, USA) and
pSmad3L (pS423/425) (Epitomics, Burlingame, California,
USA). Secondary antibodies were goat anti-rabbit IgG-HRP or
goat anti-mouse IgG-HRP (Santa Cruz Biotechnology, Santa
Cruz, California, USA). Antibodies’ sources, dilutions and buffer
conditions are given in table S1. All experiments were
performed multiple times, number of independent experiments
and densitometric analysis are given in figures S2, S3, S4, S5
and S6.
Immunofluorescent Staining of Linker Phosphorylated
Smad3
Cells were seeded with a density of 300.000 cells per well in
6-well plates without further treatment. After 1 day, cells were
washed twice with PBS pH7.4, fixed in 4% PFA/PBS for 10
minutes, permeabilized with 0.3% Triton X-100 v/v in PBS pH
7.4 for 5 min, fixed a second time with 2% PFA/PBS for 5 min
and washed 3 times in PBS. Fixed and permeabilized cells
were blocked in 1% (w/v) BSA/PBS pH 7.4 for 1h, then
incubated with rabbit-anti Smad3L antibody (Immunobiological
Laboratories No. 28029) over night at 4°C, washed 3 times in
PBS and incubated with Alexa-555-goat anti–rabbit IgG
(Molecular Probes/Invitrogen) for 50 min at room temperature.
Nuclei were stained with DRAQ5 (Biostatus Ltd, Shepshed
Leicestershire, UK) in PBS for 15 min. Fixed samples were
washed 3 times with PBS pH 7.4 and mounted on glass slides
using DakoCytomation Fluorescent Mounting Medium
(DakoCytomation, Hamburg, Germany). Confocal images were
obtained with a Leica laser scanning spectral confocal
microscope, model DM IRE2, with an HCX PL Apo 40x/1.32
numeric aperture oil objective (Leica Microsystems, Wetzlar,
Germany). Excitation was performed with an argon laser
emitting at 488 nm, a krypton laser emitting at 568 nm, and a
helium/neon laser emitting at 633 nm. Images were acquired
with a TCS SP2 scanner and Leica Confocal software, version
2.5 (Leica Microsystems).
Cell Culture
HCC-M, HCC-T, HepG2, Hep3B, HuH7, PLC/PRF/5 (PLC,
Alexander), HLE, HLF, FLC-4 and HuH6 cells were cultured in
DMEM (Lonza Group Ltd., Cologne, Germany) supplemented
with 2mM glutamine (PAA Laboratories GmbH, Cölbe,
Germany) and 10% FCS (Invitrogen, Darmstadt, Germany) at
37°C and 5% CO2 in a humidified incubator. Experiments were
conducted between passage numbers 2 and 12 without full
confluency throughout experiments. Absence of mycoplasma
contamination was confirmed by Venor®GeMtest (Minerva
Biolabs GmbH, Berlin, Germany). Prior to experiments,
medium was changed to starvation medium without FCS for at
least 7h, if not indicated otherwise. 5ng/ml TGF-β (PeproTech
GmbH, Hamburg, Germany) were used. Cell line
characteristics are given in table S2 in the supplementary data.
Smad3 Transcriptional Activity
Adherent cells were infected for 2h with adenovirus carrying
a Smad3 reporter construct, (CAGA) 9MLP-Luc [14] or control
adenovirus with β-Galactosidase [15]. After overnight
starvation, TGF-β was added for 9h. Luciferase and β-
Galactosidase activities were analyzed using Luciferase Assay
Reagent and β-Galactosidase Enzyme Assay (Promega,
Madison, WI, USA). After normalizing luciferase activity to β-
Gal expression, TGF-β dependent induction of Smad3
transcriptional activity was normalized to the untreated control
sample. Each condition was analyzed in triplicates.
Smad2 transcriptional activity
Smad2 transcription factor complexes recognize activin
response elements (ARE). Smad2 is unable to bind DNA and
needs assistance by, e.g. Fast-1, as cofactor. Hence, a
luciferase gene under the control of ARE was co-transfected
with a Fast-1 expression plasmid to evaluate Smad2/Smad4
transcriptional activity. For this, HCC cell lines were cultured at
a confluency of 70-80%. ARE-Luc, Fast-1 and a β-
Galactosidase control vector (pCR3lacZ; Invitrogen) at a ratio
of 6:2:1 were introduced into the cell using Lipofectamine 2000
(Invitrogen, Darmstadt, Germany) according to the
manufacturer’s protocol. After transfection, cells were starved
over night until treatment with TGF-β for 9h. β-Galactosidase
and Luciferase assay was performed as described above.
Smad7 Promoter Activity
β-Galactosidase control vector (pCR3lacZ; Invitrogen) and
Smad7 promoter deletion mutant, p(-625 SacI)-Smad7prom-
Luc, constructed from the 1,321-bp rat Smad7 promoter region
(-1276 to -41) [16] were transiently transfected using
Lipofectamine 2000 (Invitrogen, Darmstadt, Germany).
Immediately post-transfection, cells were starved for 24h until
treatment with TGF-β for 6h. β-Galactosidase and Luciferase
assays were performed as described above.
Knockdown of Smad2 and Smad3 with siRNA
Hep3B, HuH7 and PLC/PRF/5 cells were cultured at medium
density to perform siRNA knockdown experiments. Smad2 and
Smad3 or unspecific siRNA (Order No SI02757496,
SI00082495 and 1027281; Qiagen, Hilden, Germany) was
introduced into the cells using Lipofectamine RNAiMax
(Invitrogen, Darmstadt, Germany) according to the
manufacturer’s protocol but with 2 µl RNAiMax per ml medium.
Final siRNA concentrations were 10 µM for Hep3B and
PLC/PRF/5 and 20 µM for HuH7 cells. Knockdown was allowed
to establish for 48 h in medium supplemented with 1% heat
inactivated FCS. Cells were treated with starvation medium
supplemented with 5 ng/ml TGF-β for 1 h (proof of knockdown;
Western blot analysis) or 72 h (LDH assay). Medium for HuH7
cells additionally contained 1% heat inactivated FCS. LDH and
Western blot analysis was performed as described above.
Cytostatic TGF-β/Smad Signaling in HCC Cell Lines
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Additionally, content of LDH in adherent cells was used to
evaluate proliferation.
Clustering Analysis and Statistics
Clustering analysis was performed by using Cluster 3.0
software and the data were further visualized with TreeView
1.6 [17]. Results are shown as means +/- standard error of 3-5
(MTT Assay), 3-4 (LDH Assay), 3-4 (Real Time PCR, basal
expression), 2-3 (Real Time PCR, induced expression), 3
(Smad3 transcriptional und Smad7 promotor activity), 2-3
(Smad2 transcriptional activity) independent experiments.
Significant differences were determined by two-tailed unpaired
Student’s t test.
Results
Cytostatic TGF-β response is maintained in Hep3B,
HuH7 and PLC HCC cell lines
Sensitivity to TGF-β induced cytostasis was evaluated in 10
HCC cell lines. 2 days TGF-β treatment significantly inhibited
cell proliferation in Hep3B, HuH7 and PLC, as determined by
MTT-assay (Figure 1A, right panel), HepG2 and HuH6
displayed no or a weak response after 2 days, respectively.
However, they show a strong response 6 days upon TGF-β
addition. Proliferation of HCC-M, HCC-T, HLE, FLC-4 and HLF
was not reduced. HCC-T even displayed an increased
proliferation after 6 days treatment. In line with MTT-assay
data, expression of proliferation associated marker P21
showed the strongest induction comparing before and after
TGF-β treatment in those cell lines with TGF-β dependent
proliferation inhibition. Consistently, expression of proliferation
facilitating protein c-MYC was specifically down regulated in
cell lines sensitive to TGF-β induced proliferation control,
whereas it was even induced late in HCC-T cells (Figure 1A,
left panel, Figure S2). Western Blot analysis was not sensitive
enough to confirm weak cell death (+7%) of HepG2 upon TGF-
β treatment on protein level.
Besides controlling proliferation, TGF-β is a prominent
modulator of hepatocyte apoptosis. We analyzed apoptosis of
TGF-β treated cells by LDH release to the medium and
cleavage of PARP and Caspase3 (Figure 1B, Figure S2).
Again, Hep3B, HuH7 and PLC cells showed increased cell
death after 72h TGF-β stimulation, whereas HepG2 and HuH6
exhibited very low TGF-β induced cell death rates. Increased
cytotoxicity was accompanied by elevated levels of PARP and
Caspase3 cleavage (Figure 1B). No significant pro apoptotic
effect of TGF-β was found in the other cell lines. Our results
revealed heterogeneous cytostatic TGF-β effects in HCC cell
lines. Sensitivity for cell death induction and proliferation
inhibition generally occur in common (Hep3B, HuH7, PLC; to a
lower extent HepG2, HuH6). HCC-M, HCC-T, HLE, HLF and
FLC-4 are completely resistant to cytostatic TGF-β effects.
Upregulated TGF-β production and high expression of
inhibitory Smad7 correlate with loss of cytostatic
response in HCC cell lines
We next tried to correlate (loss of) cytostatic response with
disposability of TGF-β signaling components and dynamics of
its downstream signaling. One feature of progressed cancer
cells is TGF-β production and autocrine stimulation. Therefore,
we analyzed endogenous TGF-β expression by qRT-PCR. A
broad spectrum of expression levels was found in the cell lines
(1-10 fold) (Figure 2A). Interestingly, intrinsic levels of inhibitory
Smad7 similarly varied and relative expression strongly
correlated with that of TGF-β1 (Pearson correlation, r = 0.87, p
= 0.0011) (Figure 2A) increasing in the following order: HCC-M,
PLC, HCC-T, HepG2, Hep3B, HuH7, HLE, HLF, FLC-4 and
HuH6. Cytostatic TGF-β effects could be correlated to low
endogenous TGF-β/Smad7 expression levels (HCC-M, HCC-T,
PLC, HepG2, HuH7, exception Hep3B). The special position
taken by HCC-M and HCC-T has to be pointed out. Both cell
lines express rather low TGF-β and Smad7 levels, but do not
respond to TGF-β mediated cytostasis. This issue will be
discussed further below.
Endogenous levels of TGF-β receptor I (TβRI, ALK-5) were
relatively even within the different cell lines, although HCC-M
displayed especially high levels (Figure 2B). TGF-β receptor II
(TβRII) expression was upregulated in cell lines with an
asserved cytostatic TGF-β response, showing high (HepG2
and PLC) or medium (Hep3B and HuH7) TβRII mRNA levels
(Figure 2B). HuH6 with delayed proliferation inhibition upon
TGF-β treatment expressed low amounts of TβRII, whereas
HLE cells lacking TGF-β dependent cytostasis displayed
intermediate expression levels.
Receptor-Smad2 and co-Smad4, like TβRI, were equally
expressed in the different HCC cell lines, whereas Smad3
exhibited strikingly high mRNA and protein expression in HLE
and HLF (Figure 2C, Figure S3). However, no significant
correlation between Smad3 expression levels and the HCC
cells cytostatic response could be concluded.
TGF-β effects on expression of its signaling
components in HCC cell lines
In order to mimic the response of hepatocytes to TGF-β
secreted by other cell types, we investigated the impact of
TGF-β stimulation on expression of TGF-β signaling
components. Smad2 and Smad4 (Figure 3A, 3B, Figure S4)
levels did not vary upon 24h TGF-β treatment, whereas Smad3
(Figure 3A, 3B, Figure S4) and Smad7 (Figure 4A) expression
was significantly induced mostly in cytostasis responsive cell
lines (including HuH6), 24h and 2h after TGF-β treatment.
TGF-β-induced expression of Smad7 (Figure 4A) was inversely
correlated with intrinsic Smad7 expression, excluding HCC-M
and HCC-T (Figure 2.A).
While TβRII levels did not vary upon TGF-β stimulation, TβRI
expression was strongly induced in cytostatic responsive cell
lines (PLC, Hep3B, and HuH7) (Figure 3C), suggesting a
regulatory role for TβRI in driving the effects of TGF-β
dependent cytostasis.
Cytostatic TGF-β/Smad Signaling in HCC Cell Lines
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Figure 1.  TGF-β induces cell death and/or inhibits proliferation in PLC, HepG2, HuH6, Hep3B and HuH7.  (A) Left side: HCC
cell lines were treated with 5 ng/ml TGF-β for indicated time points. Changes in c-MYC and P21 expression were detected using
Western blot analysis with GAPDH as loading control. As HCC-T cells show a delayed TGF-β response, c-MMYC was induced after
72 h of TGF-β treatment. Right side: After TGF-β treatment for 0 (grey line), 2 (white bars) or 6 days (black bars) cell proliferation
was evaluated by MTT assays. Treated samples were normalized to the corresponding control. (B) Left side: Western blot analysis
of PARP and Caspase 3 cleavage using GAPDH expression as loading control after 0 and 48 h TGF-β treatment. In the case of
HuH7 cells, the control sample was treated with TGF-β for 3 h. Right side: Cell death induced by 5 ng/ml TGF-β over 72 h (filled
bars) was quantified by detecting LDH release normalized to total amount of LDH. Untreated samples were defined as 0 (grey line).
Significant differences are indicated as * p < 0.05, ** p < 0.01 and *** p < 0.001 (Student’s t test).
doi: 10.1371/journal.pone.0072252.g001
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Figure 2.  Expression levels of TGF-β/Smad signaling components in HCC cell lines.  Relative TGF-β1 and Smad7 (A), TGF-β
receptor I (TβRI) and II (TβRII) (B) and Smad2, Smad3, and Smad4 (C) expression levels were detected using real time PCR.
Expression of 18s rRNA was used as reference and results were analyzed with the ΔΔCt method. A strong correlation of Smad7
and TGF-β1 expression was identified by calculating the Pearson coefficient (r = 0.87; p = 0.0011) (A). Further, TβRII expression
(filled bars) was generally increased compared to the expression of TβRI (grey line) in the same cell line (B, right). Additionally, total
and phosphorylated Smad2 and Smad3 as well as basal Smad4 protein levels were evaluated by Western Blot using GAPDH as
loading control (C).
doi: 10.1371/journal.pone.0072252.g002
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Figure 3.  Induction of Smad3 and TβRI expression correlates with cytostatic responsiveness upon TGF-β treatment.  Cells
were cultured with or without 5 ng/ml TGF-β for 24 h. Changes in Smad2, Smad3 and Smad4 levels after TGF-β treatment were
evaluated by (A) Real Time PCR and (B) Western Blot analysis using 18S rRNA or GAPDH as reference genes. ◊ and ◊ ◊ indicate
which GAPDH belongs to Smad2 and Smad3 or Smad4, respectively. (C) TGF-β dependent expression levels of TGF-β Receptor I
(TβRI) and II (TβRII) were detected and correlated against untreated samples using real time PCR with 18S rRNA as reference
gene. Untreated samples are shown as grey lines, while filled bars display TGF-β treated samples. Significant differences are
indicated as * p < 0.05, ** p < 0.01 and *** p < 0.001 (Student’s t test).
doi: 10.1371/journal.pone.0072252.g003
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Figure 4.  Induction of Smad7 expression by TGF-β correlates with cytostatic responsiveness.  (A) Left side: Cells were
treated with or without TGF-β for 2 h. Smad7 expression and 18S rRNA levels as reference gene were detected by real time PCR.
Right side: For evaluation of transcriptional activity, HCC cell lines were transfected with a construct containing a luciferase gene
under control of the Smad7-promotor and treated with TGF-β for 6 h. Treated samples were correlated to untreated controls. (B)
Changes in expression levels of Smad3 target genes Bim and PAI-1 were detected after 2 h (PAI-1) or 24 h (Bim) using real time
PCR analysis with rS18 as reference gene. The tables highlight cell lines with highest CAGA activity (black fields). Significant
differences are indicated as * p < 0.05, ** p < 0.01 and *** p < 0.001 (Student’s t test).
doi: 10.1371/journal.pone.0072252.g004
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Prolonged vs short term Smad2 signaling in HCC cell
lines
As altered expression levels of signaling components may
not necessarily reflect activated signal transduction, we
investigated the phosphorylation i.e. activation of Smad2
(Figure 5A, Figure S5). Some cell lines (HCC-M, HCC-T, PLC,
Hep3B, HuH7) exhibited a prolonged pSmad2 signal after
continuous stimulation with TGF-β up to 48h, whereas others
(HepG2, HLE, HLF) faded out after 1-7h of TGF-β treatment. In
FLC-4 und HuH6 cells pSmad2 signal peaks after 1 hour and
then stabilizes on a lower level. This let us sort the cell lines
into transiently and long term activated responders with regard
to Smad2 phosphorylation.
Smad7 is a potent inhibitor of TGF-β signaling. In line, our
data suggest that Smad7 expression is critical in controlling the
duration of Smad2 activation. We found a negative correlation
(Pearson coefficient r=-0.54) between endogenous (not
induced) Smad7 expression levels and the stability of TGF-β
induced pSmad2 signals (Figure 2A, Figure 5A). Except
HepG2, all cell lines with low Smad7 expression levels (HCC-
M, HCC-T, PLC, Hep3B) exhibited a prolonged induction of
pSmad2, while cell lines with high Smad7 levels, displayed
more transient Smad2 phosphorylation. However, the latter do
not show significant Smad7 induction by TGF-β, indicating that
the TGF-β dependent negative feedback function of Smad7 is
not controlling the duration of Smad2 phosphorylation. In
contrast, induction of Smad7 correlates with CAGA reporter
system activation by TGF-β which is low in HCC-M and HCC-T
but high in PLC and Hep3B (see below) but not with Smad2
phosphorylation duration. We conclude, that basal Smad7
levels predetermine the cells sensitivity towards TGF-β induced
cytostasis. Inducibility of Smad7 itself, however, is strictly
dependent of Smad3 transcriptional activity and therefore high
in cytostatic responsive cell lines. But this induced Smad7 is
not abrogating or negatively controlling the cytostatic program
of TGF-β.
Interestingly, Smad2 dependent ARE reporter activation was
not correlated with Smad2 phosphorylation duration, but with
cytostatic sensitivity, as reflected by strong activation of
luciferase in PLC, HepG2 and HuH7 cells after TGF-β
treatment (Figure 5A). Significant, but less activation is seen in
Hep3B.
Smad3/4 dependent CAGA-Luc reporter activation and
target gene transcription correlate with cytostatic TGF-
β effects
All cell lines display immediate induction of Smad3
phosphorylation upon 1h of TGF-β treatment. The induction is
stable up to 48 hours in Hep3B, HCC-M, HLE, HuH7, HCC-T
and PLC cells, while it is only transient in HepG2, HLF, HuH6,
and FLC4 cells (Figure 5B, Figure S5). Surprisingly, Smad3
phosphorylation events were, in contrast to Smad2, not
correlated to Smad7 expression. Also, no correlation to Smad7
induction by TGF-β (Figure 4A) was detectable. Because R-
Smad phosphorylation only represents the first step in TGF-β
signaling, it may not solely explain differences in the cytostatic
TGF-β response among cell lines. Therefore, we additionally
investigated induction of TGF-β/pSmad3 dependent
transcription by measuring the relative CAGA reporter activity
after 9h TGF-β treatment. HepG2, Hep3B, PLC and HuH7 cells
exhibited relatively high CAGA-Luc-activity upon TGF-β
treatment, while the other cell lines did not (Figure 5B). We
found that the responsive cell lines have relatively little
endogenous TGF-β and Smad7 (compare Figure 2A, Figure
5B). Most obviously, we demonstrated that CAGA reporter
activation by TGF-β strongly correlated with sensitivity of the
cell lines towards cytostatic TGF-β effects. Very intriguing,
HCC-M and HCC-T display strong and prolonged TGF-β
induced Smad3 activation, however very low if any CAGA
reporter activation. In HCC-T cells, using immunofluorescence,
we identified strong nuclear staining with an antibody that
detects serine 208/213 phosphorylation at the linker region of
Smad3 (Figure 5C). Such intrinsic linker phosphorylation was
previously described to inhibit signaling of C-terminally
phosphorylated Smad3 [18] and thus, may explain the
controversy between Smad3 activation and transcriptional
activity. Such mechanism however remains to be functionally
proven.
As endogenous Smad7 levels are relatively low in TGF-β
responsive cell lines and Smad7 per se is a TGF-β target gene
of the early signature group, we compared the ability of TGF-β
to induce the Smad7 promotor and Smad7 mRNA expression
(Figure 4). We observed that TGF-β mediated Smad7 promoter
activation perfectly reflected its mRNA induction, indicating
transcriptional regulation of the expression. Furthermore, the
level of Smad7 induction paralleled that of TGF-β induced
CAGA reporter activation (PLC, HepG2, Hep3B, HuH7).
Other Smad3 dependent TGF-β target genes (Bim, PAI-1)
were also investigated (Figure 4B). In line with its apoptotic
function, Bim expression was upregulated upon TGF-β
treatment in PLC, Hep3B and HuH 7 cell lines showing a
cytostatic TGF-β response. PAI-1 expression also correlated to
TGF-β sensitivity and was induced in PLC, Hep3B and HepG2.
No coherent survival signaling status regulates
cytostatic TGF-β effects
As balance between survival and cytostatic pathways plays
an important role in determining the fate of hepatocytes and
chronic liver disease progression, we asked whether the
activity of classical survival pathways may explain differences
in cytostatic responsiveness of HCC cell lines. Expression of
BCL-2, BCL-XL, P21 and AKT as well as phosphorylation of
P38, c-JUN, ERK and AKT do not exhibit any general link to
TGF-β dependent cytostasis in the tested HCC cell lines
(Figure 6A, Figure S6). However, induction of P21 expression
(and to some extent downregulation of c-MYC) by TGF-β is a
significant marker for TGF-β dependent cytostasis (see Figure
1A).
Potential regulation of Smad3 signaling by ELF and
PRAJA
It was reported that adaptor protein ELF is essential for
Smad3 dependent TGF-β signaling and its down-regulation,
e.g. by PRAJA mediated proteasomal degradation, can
decrease Smad3 signaling and cause loss of the cytostatic
response [8,19]. Thereby, loss of ELF could support gastric
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Figure 5.  While Smad2 phosphorylation duration correlates to TGF-β and Smad7 expression, cytostatic responsiveness
relates to CAGA-reporter-activation.  HCC cell lines were treated with 5 ng/ml TGF-β for 0, 1 (3),, 7, 24 and 48 h. (A) Left side:
Western blot analysis of Smad2 phosphorylation and GAPDH expression. Right side: To evaluate TGF-β dependent transcriptional
activity of Smad2, cells were transfected with plasmids carrying a luciferase gene under control of the activin response element
(ARE) and additionally with a FAST-1 expression construct. Luciferase activity of cells treated with 5 ng/ml TGF-β for 9 h was
correlated to untreated control samples. (B) Left side: Western blot analysis of Smad1/3 phosphorylation (1: upper/3: lower band);
loading control GAPDH. Right side: TGF-β dependent transcriptional activity of Smad3 was evaluated 9 h after TGF-β treatment in
cells infected with an adenovirus carrying a luciferase gene controlled by a CAGA response element. Treated samples were
correlated to the corresponding untreated control. In the table, cell lines marked as black, show TGF-β induced cell death and
growth inhibition whereas cells marked as grey mainly react with the latter one. The gradient from white to black displays increasing
basal Smad7 expression levels. (C) Immunofluorescent detection of linker phosphorylated Smad3 in uninduced HCC-T cells. Red
fluorescence indicates nuclear localization of pSmad3L. Blue staining indicates nuclei stained with DRAQ5. Significant differences
are indicated as * p < 0.05, ** p < 0.01 and *** p < 0.001 (Student’s t test).
doi: 10.1371/journal.pone.0072252.g005
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cancer and HCC development [20–22]. Testing this mechanism
comparatively in HCC cell lines, we observed heterogeneous
expression of both proteins. However, cytostatically responsive
Hep3B and HuH7 cells expressed high levels of ELF and rather
low levels of PRAJA (Figure 6B). In HepG2 and Huh6 showing
a weaker cytostatic TGF-β response, ELF and PRAJA
expression is intermediate. HCC-M, HCC-T, HLE and HLF do
not show cytostasis upon TGF-β treatment and express
relatively low ELF, but high PRAJA. Generally spoken, relative
ELF/PRAJA ratios are higher in cytostatically responsive cell
lines than in insensitive ones.
RNAi with Smad3 conflicts TGF-β dependent cytostasis
in TGF-β sensitive HCC cells
Hierarchical clustering summarized our biochemical results
and confirmed three HCC cell line groups (Figure 7): (1)
HepG2, Hep3B, HuH7, PLC; (2) HLE, HLF, FLC-4, HuH6 as
well as (3) HCC-M plus HCC-T. The clusters differ in their
sensitivity towards TGF-β induced cytostasis, which is
correlated to different Smad7 and TGF-β expression levels,
duration of induced Smad2 phosphorylation, Smad3 and
Smad2 transcriptional activity, TβRII expression and inducibility
of TβRI mRNA.
Taken together, the clusters demonstrate that disrupted
Smad3 downstream signaling is required for loss of cytostatic
TGF-β effects in liver cancer. Additionally, TGF-β strongly
enhanced Smad3 expression and its transcriptional activity in
cell lines with retained TGF-β mediated cytostasis. For
functional proof of the critical role of Smad3 in TGF-β mediated
cytostasis, we knocked down Smad3 or Smad2 in Hep3B,
HuH7 and PLC, and investigated the resulting TGF-β effects on
apoptosis and proliferation inhibition (Figure 8). In line with our
hypothesis, we find that Smad3 knock down diminishes TGF-β
induced cytostasis, while the effect of Smad2 knock down is
comparably little. The fact that siRNA against Smad2 also
reduces Smad3 expression to some extent may even direct the
observed Smad2 knock down effects towards Smad3 function.
These results functionally confirm the predominant role of
Smad3 in cytostatic outcome of TGF-β on liver parenchymal
cells and indicate loss of Smad3 mediated downstream effects
as critical for carcinogenic transdifferentiation.
Figure 6.  Endogenous expression of survival factors and Smad3 signaling modulators PRAJA and ELF in HCC cells.  HCC
cell lines were cultured in starvation medium for 24 h. (A) Western blot analysis was performed to evaluate expression levels of Akt,
Bcl-2, Bcl-XL, p21 and GAPDH as loading control. Additionally, phosphorylation levels of ERK, c-Jun, Akt (lower band) and p38
were detected. (B) Basal PRAJA and ELF mRNA levels were quantified by Real time PCR analysis using rS18 as reference gene.
Tables in (A) and (B) highlight cell lines responding to TGF-β with cell death and growth arrest in black. Cells which mainly show an
inhibition of proliferation are marked as grey.
doi: 10.1371/journal.pone.0072252.g006
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Figure 7.  Hierarchical clustering analysis of HCC cell lines based on TGF-β/Smad signaling and cytostatic outcome.  TGF-
β related observations on the 10 HCC-derived cell lines (as summarized in Figure 9) were converted into an all-or-none fashion
(black/white boxes) to produce a matrix which was organized by hierarchical clustering algorithm. Observations were divided into 5
broad categories (A-E, left side). (A) TGF-β dependent cytostasis (black boxes: cell death >5%; proliferation inhibition >50%), (B)
basal TGF-β signaling (black boxes: 2-ΔΔCt > 2.5 for all, but >4 for Smad3), (C) induced TGF-β signaling (black boxes rel. induction of
expression 2-ΔΔCt > 2, induction of CAGA and Smad7 promoter and expression > 2.8, induction of ARE reporter > 5 ; prolonged
duration), (D) survival signaling (black boxes: >3-fold increased for pAKT total AKT, 6-fold increased for pERK; > 40% inhibition of c-
MYC), (E) basal ELF and PRAJA expression (black boxes: 2-ΔΔCt >2 and 2-ΔΔCt >1.4 respectively).
Based on the integrated above observations, clustering analysis unambiguously clustered the 10 cell lines. Beside HCC-M and
HCC-T cell lines, 2 main groups were identified: group 1 included HepG2, PLC, Hep3B, HuH7 and group 2 included HLE, HLF,
HuH6, FLC-4.
doi: 10.1371/journal.pone.0072252.g007
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Figure 8.  TGF-β induced cell death is Smad3 dependent.  RNA interference technology was used to downregulate Smad2 (S2)
and Smad3 (S3) in PLC/PRF/5 (upper panel), Hep3B (middle panel) and HuH7 (lower panel) cells. An unspecific siRNA sequence
(co) was used as control. Knockdown was allowed to take place for 48 h. Afterwards, each setup was treated with or without 5 ng/ml
TGF-β for 1 (Immunoblot) or 3 days (cell death and proliferation) (Left). Western blot analysis against phosphorylated and total
Smad2 and Smad1/3 was performed to confirm successful knockdown. GAPDH was used as loading control (Middle). After 3 days
with or without TGF-β, cell death rates were evaluated using an LDH assay. Untreated cells for each siRNA were defined as 0 (grey
line). Filled bars show TGF-β treated samples (Right). LDH content of viable (adherent) cells was used to determine proliferation
rates. TGF-β treated samples (filled bars) were related to untreated siRNA samples (grey line).
doi: 10.1371/journal.pone.0072252.g008
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Discussion
TGF-β exhibits tumor suppressive functions in early liver
disease (4). In later stages, including hepatocellular carcinoma,
it may convert to tumor promotion by amputating cytostatic
signaling branches and by facilitating EMT, migration and
invasion. In our study, we comparatively investigated 10 HCC
cell lines with regard to TGF-β signaling, its cytostatic effects
and regulation.
As visualized in the comparative overview (Figure 9), our
data suggest that HCC cell lines can be generally divided into 3
groups. This was confirmed with a hierarchical clustering
approach integrating all observations related to TGF-β/Smad
signaling and cytostatic outcome (Figure 7). The cluster
discriminates the cell lines based on an unsupervised analysis.
One group (PLC, HepG2, Hep3B, and HuH7) is responsive to
TGF-β induced apoptosis and proliferation inhibition. These
cells express relatively low endogenous levels of TGF-β and
Smad7 and TGF-β treatment induced i) TβRI expression, ii)
Smad3 expression without influencing phosphorylation
duration, iii) Smad3 dependent transcription activation (CAGA
reporter assay), iv) Smad7 promoter activity and Smad7 mRNA
expression as well as v) by trend - long term Smad2
phosphorylation.
The second group (HLE, HLF, FLC-4, to some extent HuH6)
behaves oppositely. Most importantly, they display i) loss of
cytostatic effects upon TGF-β treatment (except late
proliferation inhibition in HuH6 cells), ii) transient
phosphorylation of Smad2 upon TGF-β treatment, iii) elevated
endogenous ERK phosphorylation, iv) low induction of CAGA
reporter and v) low Smad3 and TβRI and vi) high TGF-β1 and
Smad7 expression. As HuH6 cells derive from hepatoblastoma
instead of HCC cells, this may explain its outlying behaviour
within this group in some aspects.
The third group comprising HCC-T and HCC-M that lack a
cytostatic response despite strong intrinsic P21 expression,
display some features of responsive cells like i) strong Smad3
phosphorylation, ii) low TGF-β1 and Smad7 expression, but
controversially show iii) no CAGA- or ARE reporter activation,
and iv) no TGF-β induced Smad7 promoter, Smad7, Bim or
PAI-1 mRNA. We think that this finding is probably mainly due
to the occurrence of R-Smad linker phosphorylation in these
cells, as shown for HCC-T, which is able to hinder R-Smad
transcriptional activity despite significant phosphorylation [12].
Many TGF-β signaling regulation mechanisms in healthy and
damaged organs are described. Mutations in TGF-β signaling
components are prominent in some cancer entities, including
colon and pancreas [23], whereas this seems to be a rather
rare event in HCC. Instead, major impact on downstream
signaling regulation and switching the outcome of the pathway
from tumor suppressive to tumorigenic seems to be central in
HCC. Early studies describe upregulation of TGF-β in invasive
HCC [24], low levels of TβRII in HCC with intrahepatic
metastasis [25,26] and elevated levels of Smad7 in late stage
HCC and other cancers [10,27,28]. We demonstrate that HCC
cells insensitive for cytostatic TGF-β effects express high
amounts of TGF-β and Smad7. Accordingly, we find Smad7
mRNA upregulation in 68.5% of 143 investigated human HCC
tumors as compared to surrounding non-tumorous tissue
(manuscript in preparation). Thus, high intrinsic Smad7 mRNA
levels reflect one mechanism how HCC cells evade Smad3
dependent cytostatic TGF-β effects to facilitate disease
progression. This is also reflected by previous investigations,
where ectopic Smad7 expression blunted TGF-β induced
apoptosis in Hep3B cells and Huh7 cells [29,30].
In contrast to Smad3, duration of Smad2 phosphorylation
correlated to TGF-β sensitivity in cell lines, indicating distinct
regulation and function of Smad2 and Smad3 in liver cells. An
in vivo study on the different roles of Smad2 and 3 [31]
demonstrates that hepatocytes deficient in Smad2
spontaneously acquire features characteristic of epithelial-to-
mesenchymal transition (EMT), and further that Smad2 is not
required for TGF-β stimulated growth inhibition in hepatocytes.
The authors speculate that Smad2 is anti-metastatic during
carcinogenesis, which is in line with loss of Smad2
phosphorylation in late rat HCC [32]. Accordingly, we find very
transient Smad2 phosphorylation in cytostatically insensitive
cell lines (HLE, HLF, FLC-4, HuH6) of which at least 2 (HLE
and HLF) are invasive ( [33,34] and unpublished observations
(HLE, HLF and FLC-4)).
ELF7/ β-Spectrin and PRAJA offer another TGF-β regulation
system relevant in HCC [8,35]. ELF is a cytoplasmic cofactor
required for correct subcellular localization of Smad3 and
Smad4, while PRAJA marks ELF for proteasomal degradation,
thus negatively interfering with TGF-β signaling. Except for
PLC and FLC-4, our data support such hypothesis as further
potential mechanism in HCC. In Hep3B and HuH7 cells, both
sensitive to Smad3 dependent cytostasis, ELF is highly
expressed, while PRAJA is present in low amounts. In Huh6
and HepG2, medium amounts of ELF and PRAJA correlate
with low but still significant cytostatic TGF-β response. HCC-M,
HCC-T, HLE and HLF displaying low ELF and high PRAJA
expression are lacking the TGF-β cytostatic response. Since
ELF acts downstream of R-Smad phosphorylation, its loss
does not interfere with R-Smad activation but uncouples the
latter from transcriptional regulation. Since several cell lines
display strong Smad3 phosphorylation without significant
CAGA-luc or Smad7 expression induction, our data further
support such mechanism as relevant in HCC (Figures 4, 5B,
6B). However, in PLC and FLC-4, one responsive and one
insensitive cell line, relative ELF and PRAJA expression levels
do not explain cytostatic behaviour on their own, arguing for
another mechanism to be responsible for regulation. However,
in any case, functional and more importantly causal links still
need to be demonstrated.
Hepatocyte plasticity and EMT are important constituents for
liver disease dissolvement or progression [36–41]. When
shutting down cytostatic TGF-β effects, survival pathways like
pERK and pAKT dependent cascades dominate the delicate
balance of cytostasis or survival in liver cells. As CAGA
reporter gene activation but not Smad3 phosphorylation is
affected in correlation to TGF-β induced cytostasis, our data
indicate an intracellular regulation of cytostatic responsiveness
downstream of receptor activation and Smad3 phosphorylation.
It might be reasonable to argue, that in HLE, HLF, FLC-4 and
HuH6, a shift from canonical Smad to noncanonical Smad
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signaling (e.g. Akt, ERK, JNK pathways) occurred upon TGF-β
treatment probably due to high endogenous Smad7 levels.
Accordingly, we show that HCC cell lines, which do not react
cytostatically upon TGF-β display high amounts of pERK and,
except for HuH6 cells, p-cJUN. However, also some cell lines,
which are sensitive towards TGF-β dependent cytostasis show
relatively high pERK and p-cJUN levels (Hep3B, HuH7) again
implying a complex regulation network to distinguish between
Figure 9.  Overview of basal expression levels and TGF-β response in 10 different liver cancer cell lines.  TGF-β dependent
cytostasis, induced TGF-β signalling and inhibition of MYC expression: Here, the table gives an overview about TGF-β induced
effects. The darker the field, the stronger is or, as for proliferation inhibition, the earlier occurs the described response. Basal TGF-β
signalling, survival signalling and ELF and PRAJA expression: Basal expression and protein levels of various genes were analyzed.
The results are interpreted with different gray scales with increasing darkness for higher expression levels. Scattered fields display
cells which react contradictory to the described effect. The overview highlights some correlations found by the experiments
described in Figures 1-6: a) Except for HuH6 cells, cell lines with a cytostatic response show similar responses: Strong TGF-β
dependent increase in Smad3 and TβR1 expression and activation of Smad7 and Smad3 promotor activity. The latter one is
mirrored in an induction of Smad3 target gene expression (Bim and PAI-1). b) Smad7 expression correlates to TGF-β1 mRNA, the
duration of the Smad2 activation, but also to basal ERK phosphorylation. c) In many cases HCC-M and HCC-T cells show
completely different features compared to cell lines with similar Smad7 expression.
doi: 10.1371/journal.pone.0072252.g009
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cytostatic and survival effects in HCC cell lines. Thus, it was
shown in Hep3B, PLC/PRF/5 and Huh7 that TGF-β may induce
apoptosis or survival, depending on absence or presence of
EGFR ligands [42,43]. However, HepG2 cells with a mutated
Ras/ERKs pathway exhibit apoptosis resistance (reduced rate)
that cannot be rescued through EGFR blockade.
HCC-M and HCC-T display a distinct behaviour, and
therefore, are representative for a third and very interesting
group of HCC cell lines with respect to TGF-β (Figure 7). HCC-
M and HCC-T, both display long term phosphorylation of all R-
Smads tested (Smad1, 2, 3) upon TGF-β treatment but no
reporter gene activation and cytostatic response. Rather low
Smad7 levels suggest further mechanisms of signaling
regulation. One possibility low ELF but high PRAJA expression,
which deregulates Smad3 localization and activity. As no
activation of the CAGA reporter assay was achieved by TGF-β
treatment, we also speculate that IGFBP2 via activation of Akt
and/or Yap mediated stabilization of Smad7, as recently
described for cancer stem cells (Machida et al. unpublished),
might interfere with cytostatic TGF-β/Smad signaling. Another
possibly applicable mechanism was demonstrated by
Matsuzaki and co-workers, showing that in patients with
chronic liver disease progression, JNK-dependent linker
phosphorylation of Smad3 in hepatocytes occurs, which
subsequently interferes with cytostatic R-Smad downstream
signaling [12,44,45]. Indeed, HCC-M and HCC-T show high
levels of linker phosphorylation of Smad3 and nuclear staining,
making the relevance of such mechanism probable in these
HCC cell lines and as well in human disease, since preliminary
data with HCC patient samples suggest the occurrence of
Smad3L-phosphorylation in late stage disease (data not
shown), which now will be systematically investigated.
While liver research successfully makes use of cell lines
since a long time, many contrary results on cellular processes
have been reported over time. In this regard, the presented
data will impact the understanding of human
hepatocarcinogenesis by providing a robust rationale for the
use of relevant HCC cell lines to model specific aspects of
HCC onset and progression. For the first time, we provide
comparative, correlative and relative information comprising
mechanistic details about TGF-β action and regulation in an
exhaustive set of human HCC cell lines. These new data
extend the first array based characterization of early and late
TGF-β signatures in HCC [17]. Our data strongly suggest that
the shift between tumor suppressive and tumor promoting
TGF-β effects involves different regulation of Smad3
dependent transcription, TβRI expression, Smad2 signaling
duration, and endogenous TGF-β/Smad7/TβRII levels. Further,
our results exemplify the diversity of mechanisms involved in
the regulation of TGF-β effects, even when investigating one
specific tumor entity, in this case HCC. While the exact
regulation of cytostatic TGF-β sensitivity appears to be
complex, diverse and context specific, the cell lines could be
assorted into three groups. In early stages of chronic liver
disease and onset of HCC development, TGF-β is described to
fulfil tumor suppressive and cytostatic functions, well
represented by induction of apoptosis and proliferation
inhibition by TGF-β in PLC, HepG2, Hep3B and HuH7. HLE,
HLF, FLC-4 (and Huh6) cells on the other hand more robustly
represent late stage disease with lost cytostatic TGFβ
signaling. A third group comprises HCC-T and HCC-M, also
representing late stage disease, but displaying counter
regulation of TGF-β signaling via linker phosphorylation, which
is reflected in a completely unusual setting in regard to our
biochemical analyses.
As targeting TGF-β signaling is still under discussion for
cancer treatment, our data will also influence HCC drug
development. Future research needs to determine the exact
time point of the switch from cytostatic to tumor promoting
TGF-β effects finally allowing selection of patients relevant for
anti-TGF-β therapies. Further studies on EMT and migrative,
invasive features of the cell lines are currently ongoing. Animal
studies will then determine beneficial and harmful time points to
interfere with TGF-β signaling during HCC development
making validation in patients the most important next step.
Supporting Information
Table S1.  Primary and secondary antibodies used for
immunoblot analysis. Antibodies were obtained from Cell
Signaling (Danvers, MA, USA), Santa Cruz Biotechnology
(Santa Cruz, California, USA.), Sigma Aldrich (St. Louis,
Missouri, USA), BD Bioscience (Heidelberg, Germany) or
Epitomics (Burlingame, California, USA). After blocking the
membrane with 5% non fat milk powder in TBST, the
membrane was incubated with the first antibody over night at 4
°C applying careful agitation. After removal of excessive
antibodies, the membrane was incubated with the second
antibody in TBST for 3-4 h at room temperature.
(TIF)
Table S2.  Origin of the cell line, the original patient
characteristics (age, sex, tumour stage), cell lines
passages.
(TIF)
Figure S1.  18S rRNA is a suitable reference gene for real
time PCR analysis of the used liver cancer cell lines. (A)
18S rRNA is equally expressed between the different liver
cancer cell lines. Real Time PCR experiments were performed
using 18S rRNA as reference gene. An analysis of the Ct
values of 18S rRNA revealed minor fluctuations confirming the
suitability of 18S rRNA as reference gene. Results are shown
as mean +/- SE for 3 (HCC-M and HuH6) to 4 independent
experiments. (B) TGF-beta treatment of HCC cell lines resulted
in no or negligible changes of expression of 18S rRNA in liver
cancer cell lines. The diagram shows the mean deviation (ΔCt)
of 18S rRNA Ct values from control and TGF-beta treated
samples (24 h) of the same cell line. Results are presented as
the mean +/- SE of 2-3 independent experiments.
(TIF)
Figure S2.  Densitometric analysis (ImageJ software) of
Western Blots in Figure 1 and corresponding repetitive
experiments. Results are shown as mean +/- SE of the
indicated numbers of independent experiments.
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(TIF)
Figure S3.  Densitometric analysis (ImageJ software) of
Western Blots presented in Figure 2 and corresponding
repetitive experiments. Results are shown as mean +/- SE of
the indicated numbers of independent experiments.
(TIF)
Figure S4.  Densitometric analysis (ImageJ software) of
Western Blots presented in Figure 3 and corresponding
repetitive experiments. Results are shown as mean +/- SE of
the indicated numbers of independent experiments.
(TIF)
Figure S5.  Densitometric Analysis (ImageJ software) of
Western Blots in Figure 5 and corresponding repetitive
experiments. Results are shown as mean +/- SE of the
indicated numbers of independent experiments.
(TIF)
Figure S6.  Densitometric analysis (ImageJ software) of
Western Blots in Figure 6 and corresponding repetitive
experiments. Results are shown as mean +/- SE of the
indicated numbers of experiments.
(TIF)
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